• Caribou Biosciences published long-term follow-up data from its ANTLER phase 1 trial of vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma.
• In a pivotal optimized subgroup of second-line LBCL patients (n=27), overall response rate was 82% with a 67% complete response rate.
• Median progression-free survival was 17.1 months with 12-month progression-free survival of 51%.
• The document outlines a planned randomized phase 3 trial, ANTLER-3, targeting about 250 second-line LBCL patients with progression-free survival as primary endpoint.
• Safety summary showed cytokine release syndrome in 63% of the pivotal optimized subgroup with 4% grade 3 or higher; ICANS was 4% with no grade 3 or higher.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.